Loading...
XNAS
CPRX
Market cap2.66bUSD
Jul 11, Last price  
21.81USD
1D
-0.18%
1Q
-1.09%
Jan 2017
1,977.14%
IPO
254.63%
Name

Catalyst Pharmaceuticals Inc

Chart & Performance

D1W1MN
P/E
16.23
P/S
5.41
EPS
1.34
Div Yield, %
Shrs. gr., 5y
3.34%
Rev. gr., 5y
36.89%
Revenues
492m
+23.49%
00000488,9580000000500,000102,306,337119,072,803140,833,000214,203,000398,204,000491,734,000
Net income
164m
+129.50%
-1,805,380-2,729,454-4,139,493-10,564,597-7,241,928-4,006,323-6,391,062-4,076,386-12,154,596-15,509,061-20,232,958-18,072,452-18,412,377-34,003,51431,875,33774,983,00039,482,00083,079,00071,410,000163,889,000
CFO
144m
0.00%
-455,360-1,178,532-4,424,934-8,260,412-7,683,189-3,757,405-4,985,049-5,140,366-9,875,674-12,941,783-18,015,221-17,963,503-13,742,572-25,704,40634,611,47345,034,86460,372,000116,047,000143,600,000143,600,000
Earnings
Aug 05, 2025

Profile

Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients. The company also develops Firdapse for the treatment of MuSK antibody positive myasthenia gravis, and spinal muscular atrophy type 3, as well as to treat hereditary neuropathy with liability to pressure palsies. It has license agreements with BioMarin Pharmaceutical Inc.; and collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. The company was formerly known as Catalyst Pharmaceutical Partners, Inc. and changed its name to Catalyst Pharmaceuticals, Inc. in May 2015. Catalyst Pharmaceuticals, Inc. was founded in 2002 and is based in Coral Gables, Florida.
IPO date
Nov 08, 2006
Employees
82
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
491,734
23.49%
398,204
85.90%
214,203
52.10%
Cost of revenue
259,233
311,392
112,365
Unusual Expense (Income)
NOPBT
232,501
86,812
101,838
NOPBT Margin
47.28%
21.80%
47.54%
Operating Taxes
52,374
23,101
21,640
Tax Rate
22.53%
26.61%
21.25%
NOPAT
180,127
63,711
80,198
Net income
163,889
129.50%
71,410
-14.05%
83,079
110.42%
Dividends
Dividend yield
Proceeds from repurchase of equity
141,000
1,810
2,432
BB yield
-5.41%
-0.09%
-0.12%
Debt
Debt current
369
337
Long-term debt
5,572
9,564
7,114
Deferred revenue
(1,341)
Other long-term liabilities
315
(206)
14,064
Net debt
(533,545)
(144,192)
(290,944)
Cash flow
Cash from operating activities
143,600
143,600
116,047
CAPEX
(231)
(198,524)
(29)
Cash from investing activities
(293,502)
(293,502)
9,209
Cash from financing activities
(10,857)
(10,857)
1,694
FCF
186,974
56,897
80,557
Balance
Cash
517,553
137,636
298,395
Long term investments
21,564
16,489
Excess cash
514,530
134,215
287,685
Stockholders' equity
285,346
121,393
49,991
Invested Capital
445,387
273,027
258,345
ROIC
50.15%
23.98%
32.36%
ROCE
31.82%
22.01%
32.89%
EV
Common stock shares outstanding
124,944
113,753
111,376
Price
20.87
24.15%
16.81
-9.62%
18.60
174.74%
Market cap
2,607,573
36.37%
1,912,191
-7.69%
2,071,587
183.87%
EV
2,074,028
1,767,999
1,780,643
EBITDA
270,275
119,693
103,077
EV/EBITDA
7.67
14.77
17.27
Interest
4,120
Interest/NOPBT
4.05%